Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International Capital Limited as its sole sponsor. Guoyi Technology is a leader in China's third-party SPD (Supply, Processing, and Distribution) solutions market, holding a market share of 29.2% based on projected 2024 revenue, and is the first third-party SPD solution provider in China [1][3]. Company Overview - SPD refers to an innovative supply chain model aimed at optimizing hospitals' management of medical supplies. It includes procurement management, inventory handling, and distribution management within hospitals. Traditional supply chain models rely heavily on manual operations and limited information sharing [3]. - Guoyi Technology's SPD solutions consist of three core components: SPD software systems, intelligent hardware, and professional services. These solutions help hospitals reduce operational costs and improve supply management efficiency [3]. - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including three of the eight A++ hospitals that have adopted SPD solutions [3]. Financial Information - Revenue for the years ending December 31 and September 30 is as follows: - 2023: approximately RMB 248.2 million - 2024: approximately RMB 377.9 million - 2025 (as of September 30): approximately RMB 306 million [7][8]. - The total profit and comprehensive income for the same periods are: - 2023: approximately RMB 12.3 million - 2024: approximately RMB 57.6 million - 2025 (as of September 30): approximately RMB 43.2 million [9]. - Gross profit margins for the respective years are: - 2023: 37.1% - 2024: 41.8% - 2025 (as of September 30): 38.8% [10]. Industry Overview - The SPD solutions market in China is projected to grow significantly, with the total market size increasing from RMB 18.4 billion in 2019 to RMB 181.5 billion by 2024, reflecting a compound annual growth rate (CAGR) of 58.1%. By 2029, the market is expected to reach RMB 1,057.4 billion, with a CAGR of 42.3% from 2024 to 2029 [11][12]. - The total transaction value of medical consumables through SPD solutions is expected to grow from RMB 15.9 billion in 2019 to RMB 151.3 billion by 2024, with a CAGR of 56.9%. By 2029, it is projected to reach RMB 724.9 billion [11][12]. - The third-party SPD solutions market is expected to grow from RMB 1 billion in 2019 to RMB 11 billion by 2024, with a CAGR of 75.7%. By 2029, it is projected to reach RMB 9.6 billion, with a CAGR of 53.3% from 2024 to 2029 [14][15].

Core Viewpoint - Anhui Zhongji Guoyi Medical Technology Co., Ltd. (referred to as "Guoyi Technology") has submitted a listing application to the Hong Kong Stock Exchange, aiming to capitalize on its position as a leader in China's third-party SPD (Supply, Processing, and Distribution) solutions market, with a market share of 29.2% as of 2024 [1][3]. Company Overview - SPD refers to an innovative supply chain model that optimizes the supply and management of medical materials in hospitals, addressing inefficiencies in traditional supply chain methods that rely heavily on manual operations and limited information sharing [3]. - Guoyi Technology's SPD solutions include three core components: SPD software systems, intelligent hardware, and professional services, which help hospitals reduce operational costs and improve supply management efficiency [3]. - As of September 30, 2025, Guoyi Technology's SPD solutions have been deployed in 116 hospitals across 13 provinces in China, including three of the eight A++ hospitals that have adopted SPD solutions [3]. Product Development - In addition to SPD solutions, Guoyi Technology has developed an in-hospital IDS (Intelligent Distribution System) solution based on IoT and AI technologies, set to launch in 2024 [4]. - The IDS solution will cover logistics for various materials in complex hospital environments, including medical consumables, pharmaceuticals, and medical waste, across critical operational areas such as operating rooms and pharmacies [4]. Financial Information - For the fiscal year ending December 31, 2023, Guoyi Technology reported revenues of approximately RMB 248.2 million, with projected revenues of RMB 377.9 million for 2024 [6]. - The gross profit for the same periods was RMB 92.0 million in 2023 and is expected to rise to RMB 158.2 million in 2024, indicating a gross margin increase from 37.1% to 41.8% [6][8]. - The net profit for the nine months ending September 30, 2024, is projected to be RMB 57.6 million, up from RMB 12.3 million in 2023 [7]. Industry Overview - The overall market for SPD solutions in China is projected to grow from RMB 18.4 billion in 2019 to RMB 181.5 billion by 2024, with a compound annual growth rate (CAGR) of 58.1% [9][10]. - The market for medical consumables through SPD solutions is expected to increase from RMB 15.9 billion in 2019 to RMB 151.3 billion by 2024, with a CAGR of 56.9% [9][10]. - The third-party SPD solutions market is anticipated to grow from RMB 1 billion in 2019 to RMB 11 billion by 2024, with a CAGR of 75.7% [12][13].

Group 1 - The core viewpoint of the article highlights that Jianfa Zhixin (301584) has been operating in the SPD business for many years, with a significant focus on SPD management services for tertiary public hospitals [1] - The gross profit margin for the company's SPD management services is projected to be in the range of 30%-40% from 2022 to 2024 [1]

Group 1 - The SPD concept is gaining traction in the secondary market, with companies like Seli Medical, Guoke Hengtai, and Chongyao Holdings seeing significant stock price increases [1] - SPD stands for Supply, Processing, and Distribution, representing a modern supply chain management model in healthcare [1] - SPD business involves operators signing contracts with medical institutions to centralize the supply, inventory, processing, and distribution of medical materials [1] Group 2 - The SPD model allows companies to build smart supply chain management platforms for medical institutions, providing diversified services to enhance operational efficiency [1] - The introduction of lean management in SPD can reduce waste, optimize processes, and lower procurement costs for medical institutions [1] - The analyst predicts a substantial market demand for SPD in Chinese hospitals due to the rising costs of medical supplies, which account for 50% to 55% of hospital expenses [2] Group 3 - Companies are actively responding to the growing interest in SPD and hospital information technology on investor platforms [2] - Seli Medical claims a significant market share in SPD projects and aims to expand through regional cooperation [2] - Chongyao Holdings has implemented around 80 SPD projects across 14 provinces, serving nearly 70 medical institutions [2]

Group 1 - The core viewpoint of the article highlights McKesson's financial performance, showing a significant increase in revenue but a decline in net profit [1][2] - As of June 30, 2025, McKesson reported total revenue of $97.827 billion, representing a year-over-year growth of 23.39% [1] - The company's net profit attributable to shareholders was $784 million, which reflects a year-over-year decrease of 14.32% [1] Group 2 - On August 6, McKesson announced a cumulative share repurchase amounting to $581 million for the first quarter of 2025 [2] - McKesson is recognized as a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology, specialty care, and healthcare information technology [2] - The company operates through three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions [2]

Group 1 - The company has established a special account for the storage of raised funds and signed a four-party supervision agreement to ensure compliance with regulations and protect investors' rights [2][3] - The total amount raised from the issuance of convertible bonds is RMB 543.31 million, with a net amount of RMB 532.698 million after deducting related expenses [1] - The special account is exclusively for the use of funds related to the medical consumables centralized operation service project, and cannot be used for other purposes [3][4] Group 2 - The four-party supervision agreement involves the company, its subsidiary, the underwriting institution, and the bank, ensuring proper management of the raised funds [2][3] - The agreement stipulates that the underwriting institution will conduct ongoing supervision and can perform site investigations and inquiries regarding the special account [3][4] - The agreement will remain effective until all funds in the special account are fully utilized and the account is legally closed [4]